medigraphic.com
ISSN 2221-2434 (Electronic)

2021, Number 2

<< Back Next >>

Finlay 2021; 11 (2)

Genetic and molecular biology implications in the surgical treatment of gastric cancer

Aguirre FRE, Serra VMÁ

Language: Spanish
References: 28
Page: 189-199
PDF size: 513.56 Kb.


ABSTRACT

Gastric cancer is one of the leading causes of death from neoplasms in the world. Current clinical practice guidelines offer treatment models that involve surgery, radiotherapy, chemotherapy, immunotherapy and therapy directed at specific growth receptors, however, genetic and molecular biology aspects are not always taken into account in medical practice. The objective of this review is to articulate the most relevant current aspects of genetics and molecular biology in relation to gastric cancer, to integrate them into the clinical guidelines of patients and relatives with the diagnosis or at risk of suffering from this type of neoplasia. For them, genetic advances and syndromes related to gastric cancer, molecular classifications and implications in their management were reviewed. The databases Google Scholar, Elsevier, and PubMed were used in the last 10 years, selecting the most important full-text from a qualitative point of view. The integration of personal and family history with genetic elements needs to be taken into account in the diagnostic management and prevention of this disease. The inclusion of genetic and molecular elements in all clinical practice guidelines is suggested.


REFERENCES

  1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence worldwide in 2018[Internet]. Ginebra:International Agency for Research on Cancer;2018[citado 10 May 2020]. Disponible en: Disponible en: https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf .

  2. Slavin TP, Weitzel JN, Neuhausen SL, Schrader KA, Oliveira C, Karam R. Genetics of gastric cancer: what do we know about the genetic risks? Transl Gastroenterol Hepatol. 2019;4(1):55.

  3. Aguirre RE, Serra MA, Aguirre ME. Visión holística de nuevos desafíos: paradigmas tecnológicos y fundamentos bioéticos en la Medicina futurista. Rev haban cienc méd[Internet]. 2017[citado 15 Ago 2019];16(5):[aprox. 10p.]. Disponible en: Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2017000500016&lng=es .

  4. Machlowska J, Maciejewski R, Sitarz R. The Pattern of Signatures in Gastric Cancer Prognosis. Int J Mol Sci. 2018;19(6):1658.

  5. Ferreira M, Ferreira H, Rey JA, Pinto GR, Cardoso M, Moreira CA, et al. YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process. Oncotarget. 2016;7(51):85393-410.

  6. Amigo JD, Opazo JC, Jorquera R, Wichmann IA, García BA, Alarcon MA, et al. The Reprimo Gene Family: A Novel Gene Lineage in Gastric Cancer with Tumor Suppressive Properties. Int J Mol Sci. 2018;19(7):1862.

  7. Chintalacheruvu LM, Shaw T, Buddam A, Diab O, Kassim T, Mukherjee S, et al. Major hereditary gastrointestinal cancer syndromes: a narrative review. J Gastrointest Liver Dis. 2017;26(2):157-63.

  8. Jansen AML, Goel A. Mosaicism in Patients With Colorectal Cancer or Polyposis Syndromes: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18(9):1949-60.

  9. Bhattacharya P, McHugh TW. Lynch Syndrome[Internet]. Treasure Island:StatPearls;2020[citado 2 Feb 2021]. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/28613748/.

  10. Lv XP. Gastrointestinal tract cancers: Genetics, heritability and germ line mutations. Oncol Lett. 2017;13(3):1499-1508.

  11. Spoto CPE, Gullo I, Carneiro F, Montgomery EA, Brosens LA. Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing. Semin Diagn Pathol. 2018;35(3):170-83.

  12. Rudloff U. Gastric adenocarcinoma and proximal polyposis of the stomach: diagnosis and clinical perspectives. Clin Exp Gastroenterol. 2018;11(1):447-59.

  13. Lérias JR, Paraschoudi G, Silva I, Martins J, de Sousa E, Condeço C, et al. Clinically Relevant Immune Responses against Cytomegalovirus: Implications for Precision Medicine. Int J Mol Sci. 2019;20(8):1986.

  14. Bagno A, Martini R. Bridging the gap between basic research on microcirculation and clinical world: The translational marriage between engineering and medicine. Clin Hemorheol Microcirc. 2019;71(3):357-63.

  15. Deans C, Maggert KA. What do you mean, "Epigenetic"? Genetics. 2015;199(4):887-96.

  16. Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol. 2018;24(26):2818-32.

  17. Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-9.

  18. Tian SB, Yu JC, Kang WM, Ma ZQ, Ye X, Cao ZJ, et al. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer. Asian Pac J Cancer Prev. 2014;15(15):6295-300.

  19. Virgilio E, Proietti A, D'Urso R, Cardelli P, Giarnieri E, Montagnini M, et al. Measuring Intragastric Tumor Markers in Gastric Cancer Patients: a Systematic Literature Review on Significance and Reliability. Anticancer Res. 2017;37(6):2817-21.

  20. Li F, Li S, Wei L, Liang X, Zhang H, Liu J. The correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment. Biomarkers. 2013;18(7):632-7.

  21. Kotzev AI, Draganov PV. Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing? Gastrointest Tumors 2018;5(1-2):1-13.

  22. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014;4(1):64.

  23. Lizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H. Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses. 2012;4(12):3420-39.

  24. Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP. Hepatocyte growth factor/MET in cancer progression and biomarker discovery. Cancer Sci. 2017;108(3):296-307.

  25. Panarese I, De Vita F, Ronchi A, Romano M, Alfano R, Di Martino N, et al. Predictive biomarkers along gastric cancer pathogenetic pathways. Expert Rev Anticancer Ther. 2017;17(5):417-25.

  26. Committee of the Korean Gastric Cancer Association. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer. 2019;19(1):1-48.

  27. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1-21.

  28. Skill N, Maluccio M. Contemporary paradigm for the evaluation and treatment of hereditary gastric cancer. Transl Gastroenterol Hepatol. 2019;4(1):14.




2020     |     www.medigraphic.com